Tagged with Opinion,

Vaccines Need to Stop the Spread of COVID or Protect against New Variants & Other Viruses to Disrupt Market & Reduce Healthcare Burden

Opinion Vaccines Need to Stop the Spread of COVID or Protect against New Variants & Other Viruses to Disrupt Market & Reduce Healthcare Burden

Opinion Airfinity’s Dr Patricia Gallego highlights the persistent threat that COVID-19 continues to present to patients and healthcare systems around the world and outlines the urgent need for more vaccine breakthroughs in 2023 to combat the “tripledemic” burden of COVID-19, flu and RSV. 2023 will be a pivotal year for…

Middle East Regulatory Landscape: Collaboration, Agility, and Adaptation

MENA Middle East Regulatory Landscape: Collaboration, Agility, and Adaptation

MENA Amira Younes of AbbVie UAE examines how the COVID-19 pandemic highlighted the need for new ways of thinking about delivering regulatory effectiveness and efficiency in the region, and for flexibility from all stakeholders to ensure that therapies continue to reach patients in a timely manner. Most countries in the…

Maintaining Good Clinical Practice During War

Ukraine Maintaining Good Clinical Practice During War

Ukraine Igor Bondarenko of Ukraine’s Dnipro State Medical University, Evgeny Levenko from clinical trials company, ARENSIA, and Olena Popova from IQVIA offer their perspectives on maintaining quality and ensuring participant protection in clinical trials in Ukraine during wartime. The ongoing war places unprecedented pressure on the healthcare system and clinical…

Why We Need to Work Year-Round to Reduce the Burden of Rare Respiratory Diseases

Rare Diseases Why We Need to Work Year-Round to Reduce the Burden of Rare Respiratory Diseases

Rare Diseases With February’s Rare Disease Day behind us, it can be easy to forget the impact of these diseases on individuals, their families and care givers, and our communities throughout the other 11 months of the year. But if we – in healthcare, in government and in academia – are to…

After Four Decades of Battling to Save Lives from HIV/AIDS, Where Are We? (Part Two)

Africa After Four Decades of Battling to Save Lives from HIV/AIDS, Where Are We? (Part Two)

Africa The second in a three-part series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come (read part one here) from Lenias Hwenda of Medicines for Africa. Here, Hwenda shines a light on the importance of preventing mother-to-child transmission…

Ethical Considerations: Clinical Research in Wartime Ukraine and Beyond

Ukraine Ethical Considerations: Clinical Research in Wartime Ukraine and Beyond

Ukraine The March edition of DIA’s Global Forum magazine features a special section on clinical research in Ukraine, over one year on from the beginning of the Russian invasion. Here, Chieko Kurihara of Kanagawa Dental University, Japan; Victoriia Dobrova of Ukraine’s National University of Pharmacy; Francis P. Crawley of the Good…

From COVID-19 Pandemic to War: Clinical Trial Industry Powers on Under Extreme Conditions

Ukraine From COVID-19 Pandemic to War: Clinical Trial Industry Powers on Under Extreme Conditions

Ukraine The March edition of DIA’s Global Forum magazine features a special section on clinical research in Ukraine, over one year on from the beginning of the Russian invasion. Anina Adelfio of the Association of Clinical Research Organizations (ACRO) looks back on an extremely challenging two years for the clinical trial…

Improving the EBITDA of a $4.3 Trillion Investment in Healthcare

Global Improving the EBITDA of a $4.3 Trillion Investment in Healthcare

Global Blue Spoon Consulting’s John G. Singer takes aim at the recent anti-Big Pharma rhetoric around the drug pricing crisis in the US, instead calling for a more holistic view of the situation, acknowledging the role being played by pharmacy benefit managers (PBMs). More importantly, Singer sees a new approach to…

PBM Association: Washington Must Remain Focused on Root Cause of High Drug Prices

USA PBM Association: Washington Must Remain Focused on Root Cause of High Drug Prices

USA As debate rages over where to lay the blame for the USA’s drug affordability crisis, Katie Payne, senior vice president for strategic communications for the Pharmaceutical Care Management Association (PCMA) sets out a defence of the country’s pharmacy benefit manager (PBM) industry. Payne instead raises concerns with big drug companies’…

The Inflation Reduction Act: What Needs Fixing & What’s Left to Address In Terms of Patient Affordability

USA The Inflation Reduction Act: What Needs Fixing & What’s Left to Address In Terms of Patient Affordability

USA PhRMA President and CEO Stephen J. Ubl takes aim at the health insurers and pharmacy benefit managers (PBMs) driving medicines costs up in the US, and the Inflation Reduction Act (IRA) which he sees as failing to address the patient affordability conundrum. Ubl calls for a policy framework able to…

COVID-19: An Opportunity to Turn Around Low Elderly Vaccination Uptake in China?

China COVID-19: An Opportunity to Turn Around Low Elderly Vaccination Uptake in China?

China Vaccinating the elderly has been a key factor in ensuring protection against fatality during COVID-19, writes Bridge Consulting’s Stefania Jiang. However, the experience of it in China has been one of ups and downs as vaccine hesitancy and a slew of social issues have greatly affected uptake. But ultimately, this…

After Four Decades of Battling to Save Lives from HIV/AIDS, Where Are We?

Africa After Four Decades of Battling to Save Lives from HIV/AIDS, Where Are We?

Africa In the first of a series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come, Lenias Hwenda of Medicines for Africa shares her personal meditations on the HIV pandemic, the impact of expanded access to antiretroviral therapy, and…

1 … 9 10 11 … 39